vimarsana.com
Home
Live Updates
U.S. FDA Approves Pfizers BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B : comparemela.com
U.S. FDA Approves Pfizer's BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
A one-time dose of BEQVEZ has reduced bleeds post-treatment compared to standard of care with a median of zero bleeds after up to three years of follow-up, providing sustained bleed protection and...
Related Keywords
United States ,
Canada ,
Adam Cuker ,
Thromb Haemost ,
Kim Phelan ,
Aamir Malik ,
Drug Administration ,
Linkedin ,
Pfizer Inc ,
Hemophilia Thrombosis Program ,
Facebook ,
Pfizer ,
Value Health ,
European Medicines Agency ,
Exchange Commission ,
Youtube ,
Coalition For Hemophiliab We ,
Centers For Disease ,
World Federation Of Hemophilia ,
Penn Comprehensive ,
Hemophilia Thrombosis ,
World Federation ,
Executive Vice President ,
Chief Operating Officer ,
Biologics License Application ,
European Marketing Authorization Application ,
Pfizer Gene Together ,
Safety Information ,
Prescribing Information ,
Breakthroughs That Change Patient Lives ,
Prescription Medicines ,
Annual Report ,
Looking Information ,
Factors That May Affect Future ,
Disease Control ,
Markets ,
comparemela.com © 2020. All Rights Reserved.